CDCA5 and its associated pathways have been widely investigated in cancers, such as the PI3K/AKT/mTOR signaling pathway in breast cancer[45] and the ERK signaling pathway in bladder cancer.[46] Some scholars have found a decrease in the expression of CDK1 in the siCDCA5 cell line,[46] which has been confirmed to be an important protein in the cell cycle. This evidence concerns the gene AKT1 and urinary bladder carcinoma.